Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
7.95
+0.01 (0.13%)
Mar 28, 2024, 11:12 AM EDT - Market open
Actinium Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ATNM stock have an average target of 26.9, with a low estimate of 11.6 and a high estimate of 50. The average target predicts an increase of 238.36% from the current stock price of 7.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ATNM stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +528.93% | Mar 26, 2024 |
Maxim Group | Maxim Group | Strong Buy Maintains $20 → $30 | Strong Buy | Maintains | $20 → $30 | +277.36% | Mar 19, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +528.93% | Mar 19, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +528.93% | Mar 11, 2024 |
B. Riley Securities | B. Riley Securities | Strong Buy Maintains $20 → $16 | Strong Buy | Maintains | $20 → $16 | +101.26% | Dec 11, 2023 |
Financial Forecast
Revenue This Year
183.77K
from 1.03M
Decreased by -82.16%
Revenue Next Year
3.95M
from 183.77K
Increased by 2,049.39%
EPS This Year
-2.09
from -1.37
EPS Next Year
-1.90
from -2.09
Revenue Forecast
Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | 1.1M | 23.2M | 157.6M | 361.4M | 636.3M | 865.0M |
Avg | 183,773 | 4.0M | 72.2M | 173.5M | 311.6M | 454.4M |
Low | n/a | n/a | 28.4M | 82.1M | 153.4M | 279.3M |
Revenue Growth
Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | 10.2% | 12,527.0% | 3,890.1% | 400.7% | 266.8% | 177.6% |
Avg | -82.2% | 2,049.4% | 1,727.5% | 140.3% | 79.7% | 45.8% |
Low | - | - | 618.8% | 13.8% | -11.6% | -10.4% |
EPS Forecast
EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | -2.07 | -1.51 | 0.91 | 3.92 | 7.86 | 10.71 |
Avg | -2.09 | -1.90 | -0.23 | 1.70 | 4.39 | 7.34 |
Low | -2.07 | -2.61 | -0.87 | -0.38 | 1.10 | 4.12 |
EPS Growth
EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | 361.7% | 143.9% |
Avg | - | - | - | - | 157.8% | 67.2% |
Low | - | - | - | - | -35.6% | -6.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.